Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment

OBJECTIVE: We undertook this phase III study to evaluate baricitinib, an orally administered JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis (RA) who had received no or minimal conventional synthetic d...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Arthritis Rheumatol
मुख्य लेखकों: Fleischmann, Roy, Schiff, Michael, van der Heijde, Désirée, Ramos‐Remus, Cesar, Spindler, Alberto, Stanislav, Marina, Zerbini, Cristiano A. F., Gurbuz, Sirel, Dickson, Christina, de Bono, Stephanie, Schlichting, Douglas, Beattie, Scott, Kuo, Wen‐Ling, Rooney, Terence, Macias, William, Takeuchi, Tsutomu
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: John Wiley and Sons Inc. 2017
विषय:
Rheumatoid Arthritis
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5347954/
https://ncbi.nlm.nih.gov/pubmed/27723271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.39953
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन